DOI: 10.36347/sjams.2019.v07i04.038

Pages: 1553-1561

Background: Carotid Intima Media Thickness (CIMT) found to correlate with atherosclerosis burden and predict cardiovascular (CVD) risk. As immune mechanism is involved in pathogenesis of atherosclerosis, efficacy of immune modulator Hydroxychloroquine (HCQS) is evaluated in its management. Material and Method: Comparative clinical efficacy of Atorastatin, Atorvastain plus HCQS, and HCQS was evaluated, based on CIMT regression, in patients with associated CVD risks. Results: 114 patients completed the study, were clinically evaluated in three groups: Group-1 (Atorvastatin), Group- 2 (Atorvastatin plus HCQS) and Group-3 (HCQS). Majority of patients were in 51–70 age. Major diseases with CVD risk were diabetes mellitus, hypertension, CAD, obesity or in combinations. As CIMT measurement correlates with CVD risk, its regression measured revealed appreciable CIMT regression in Group -2 and Group–3 than Group – 1 at 12 2 months. Diabetic patients with or without comorbidities had shown better regression than others. CIMT regression in obese subset was unremarkable. Conclusion: HCQS with statins was almost as effective as when given alone in reducing CIMT, hence useful in reduction in CVD risk. HCQS may be tried as an adjuvant with statin in atherosclerosis CVD risks management